A new pricing platform for a new generation of indication and combination oncology therapies in Europe
Total raised: $3M
Founded date: 2017
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 23.11.2018 | Seed | $3M | - |
Mentions in press and media 7
| Date | Title | Description |
| 23.11.2018 | PharmaCCX Raises $3 Million To Help Patients Get Medication Faster | PharmaCCX is a Boston-based company that is developing a technology platform enabling pharmaceutical companies and payers to speed up pricing negotiations in order to get medication to patients in need faster. “We are delighted to partner w... |
| 20.11.2018 | PharmaCCX Raises $3M Seed Round | PharmaCCX, a technology exchange platform that enables pharmaceutical companies and payers to more quickly agree on therapy pricing, has raised a $3 million seed round. The financing was led by Accel, with participation from Atlantic Labs, ... |
| 20.11.2018 | PharmaCCX Announces $3M Seed Funding | BOSTON, MA, PharmaCCX has raised a $3 million seed round. >> Click here for more funding data on PharmaCCX >> To export PharmaCCX funding data to PDF and Excel, click here PharmaCCX, a technology exchange platform that en... |
| 20.11.2018 | PharmaCCX Raises $3M Seed Round | PharmaCCX, a technology exchange platform that enables pharmaceutical companies and payers to more quickly agree on therapy pricing, has raised a $3 million seed round. The financing was led by Accel, with participation from Atlantic Labs, ... |
| 20.11.2018 | PharmaCCX Raises $3M in Seed Funding | PharmaCCX, a Boston, MA-based technology exchange platform that enables pharmaceutical companies and payers to agree on therapy pricing, raised $3m in seed funding round. The round was led by Accel, with participation from Atlantic Labs, Gr... |
| - | Four reasons you should be optimistic about the future of drug pricing | By Nathan Sigworth Creative pricing models aimed at increasing patient access to innovative therapies have been kicking around for a while. But why have such approaches never scaled across the industry? The fact that these approaches have n... |
| - | Why 2021 is the right time to scale managed entry agreements | By Nathan Sigworth As we understand more about the science of cancer, we are seeing new innovative treatments coming out of R&D pipelines. These new drugs attack cancer through one mechanism of action, or another, or multiple. With ever... |